Metabolic Basis of Bacterial Community Function in the Cystic Fibrosis Airway

囊性纤维化气道细菌群落功能的代谢基础

• 批准号: 10293007
• 负责人: George A. O'Toole
• 金额: $ 46.65万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-02 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10293007
• 关键词: Acute; Acute Disease; Antibiotics; Antimicrobial Resistance; Bacteria; Big Data; Bioinformatics; Cell Culture Techniques; Chronic; Chronic Disease; Clinical; Clinical Data; Communities; Complex; Computer Models; Consumption; Culture-independent methods; Cystic Fibrosis; Data; Data Set; Development; Disease; Disease Outcome; Dose; Energy-Generating Resources; Event; Exhibits; Experimental Models; Exposure to; Feeding Patterns; Genetic Diseases; Genetic study; In Vitro; Individual; Infection; Lung; Lung infections; Machine Learning; Measures; Metabolic; Metadata; Microbe; Microbial Physiology; Minimum Inhibitory Concentration measurement; Modeling; Morbidity - disease rate; Mucous body substance; Mutation; Nature; Organism; Outcome; Outcome Measure; Output; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Pseudomonas aeruginosa; Pseudomonas aeruginosa infection; Pulmonary Function Test/Forced Expiratory Volume 1; Regimen; Research; Resistance; Role; Sampling; Sputum; Staphylococcus aureus; Streptococcus; Structure; Testing; Virulence; Work; antibiotic tolerance; antimicrobial; antimicrobial drug; bacterial community; base; bioinformatics tool; cystic fibrosis airway; cystic fibrosis infection; cystic fibrosis patients; experimental study; feeding; improved; in silico; in vitro Model; in vivo; insight; member; metabolomics; microbial; microbial community; mortality; novel; novel therapeutics; pathogenic bacteria; polymicrobial biofilm; polymicrobial disease; pulmonary function; pulmonary function decline; success; tool; translational impact

Abstract. Cystic fibrosis (CF) is a fatal genetic disease characterized by overproduction of mucus in the lungs followed by chronic lung infections. Conventional wisdom has been that most CF lung infections involve a single dominant organism, most commonly the pathogenic bacterium Pseudomonas aeruginosa. Advances in culture-independent techniques have revealed that CF lung infections are rarely mono-microbial and instead usually involve complex microbial communities, yet the interspecies interactions that drive these communities are poorly understood. Furthermore, numerous studies have demonstrated that polymicrobial infections are more difficult than mono-microbial infections to eradicate with antibiotics, leading to the concept of recalcitrant communities. The mechanisms underlying recalcitrance are thought to involve synergistic interactions between community members, but very little data are available to understand this phenomenon. Combined with the realization that many CF patients respond poorly to available antibiotic regimens compels a more detailed understanding of interspecies interactions and their impacts on antibiotic recalcitrance to improve the treatment of CF infections, as well as other polymicrobial diseases. Here, we combine big-data bioinformatics, in silico computational modeling and in vitro culture experiments to gain insights into the metabolic interactions that drive CF disease outcomes and antibiotic recalcitrance. The research will leverage an available data set of hundreds of CF patient samples that provide both bacterial composition data and clinical metadata, including measures of lung function. These samples will be clustered according to their measured compositions and metabolic capabilities predicted through computational metabolic modeling to test the hypothesis that the vast complexity of these many bacterial communities can be collapsed into a small number of model communities that capture most of the observed metabolic variability. These computational predictions will be tested by developing in vitro cell culture models that recapitulate the most important metabolic features of the in vivo polymicrobial communities (Aim 1). By applying bioinformatics and modeling to the same clinical data, we will test the hypothesis that community metabolic features drive disease outcomes and the virulence potential of these communities (Aim 2). Finally, we will interrogate the clinical data and in vitro communities to test the hypothesis that community metabolic features drive antibiotic recalcitrance and differentiate community responsiveness to antibiotics according to these metabolic features (Aim 3). Our research will yield novel insights into how complex polymicrobial communities are compositionally structured, interact metabolically, contribute to disease and respond to antibiotics. Moreover, the research will validate in vitro models that offer the potential for development of novel antimicrobial strategies to better treat chronic, polymicrobial infections in CF and other diseases. Our transdisciplinary team offers the necessary expertise in bioinformatics, computational modeling, microbial physiology and CF polymicrobial infections to tackle this complex problem.

摘要。囊性纤维化（CF）是一种致命的遗传性疾病，其特征是肺部粘液分泌过多